EVMN
Evommune, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeEvommune expanded its pipeline via a $30M in-license of EVO570 (VAT1 degrader) from Hinova, funded by a $30M private placement at $6.04/share—78% below February pricing—signaling investor skepticism. Q3 results showed zero revenue, a $31M net loss (up 148% YoY), and 43% higher operating expenses, though the concurrent financing extended cash runway to H2 2029.
Red flags
- •Revenue collapsed to zero in Q3 2026 from $10M in Q3 2025 (prior collaboration ended)
- •Net losses more than doubled YoY to $31M despite no revenue generation
- •Private placement priced 78% below prior raise in February 2026, indicating significant loss of investor confidence
- •Operating expenses surged 43% YoY to $33M with no corresponding revenue; path to profitability unclear
- •Analyst downgrade to 'strong sell' by Wall Street Zen (November 14, 2026) offset modest HC Wainwright estimate lift
- •Early-stage pipeline (EVO301 Phase 2a, EVO570 newly in-licensed) carries high clinical and commercial risk with 2029 cash runway dependent on burn rate
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).